{
    "organizations": [],
    "uuid": "63aa9db8b5c12e862376c30d84e1c97e3e5f884f",
    "author": "",
    "url": "https://www.reuters.com/article/brief-roche-says-late-stage-study-shows/brief-roche-says-late-stage-study-shows-genentechs-tecentriq-and-avastin-reduced-the-risk-of-disease-worsening-or-death-by-26-pct-in-certain-people-with-advanced-kidney-cancer-idUSFWN1PV1EG",
    "ord_in_thread": 0,
    "title": "BRIEF-Roche Says Late-stage Study Shows Genentech's Tecentriq And Avastin Reduced The Risk Of Disease Worsening Or Death By 26 Pct In Certain People With Advanced Kidney Cancer",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 5 (Reuters) - Roche Holding Ag:\n* PHASE III IMMOTION151 STUDY SHOWED GENENTECH’S TECENTRIQ (ATEZOLIZUMAB) AND AVASTIN (BEVACIZUMAB) REDUCED THE RISK OF DISEASE WORSENING OR DEATH BY 26 PERCENT IN CERTAIN PEOPLE WITH ADVANCED KIDNEY CANCER\n* GENENTECH SAYS TECENTRIQ AND AVASTIN MET CO-PRIMARY ENDPOINT\n* GENENTECH - INITIAL OBSERVATIONS FROM CO-PRIMARY ENDPOINT OF OVERALL SURVIVAL IN OVERALL STUDY POPULATION WERE “ENCOURAGING, BUT ARE STILL IMMATURE”\n* GENENTECH - RATE OF TREATMENT-RELATED GRADE 3-4 ADVERSE EVENTS LOWER WITH TECENTRIQ & AVASTIN COMBINATION VERSUS SUNITINIB IN ALL TREATED PATIENTS Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-06T00:17:00.000+02:00",
    "crawled": "2018-02-06T00:32:26.011+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "roche",
        "holding",
        "ag",
        "phase",
        "iii",
        "immotion151",
        "study",
        "showed",
        "genentech",
        "tecentriq",
        "atezolizumab",
        "avastin",
        "bevacizumab",
        "reduced",
        "risk",
        "disease",
        "worsening",
        "death",
        "percent",
        "certain",
        "people",
        "advanced",
        "kidney",
        "cancer",
        "genentech",
        "say",
        "tecentriq",
        "avastin",
        "met",
        "endpoint",
        "genentech",
        "initial",
        "observation",
        "endpoint",
        "overall",
        "survival",
        "overall",
        "study",
        "population",
        "encouraging",
        "still",
        "immature",
        "genentech",
        "rate",
        "grade",
        "adverse",
        "event",
        "lower",
        "tecentriq",
        "avastin",
        "combination",
        "versus",
        "sunitinib",
        "treated",
        "patient",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}